| Lesion . | Response . | 30 mg (N = 6) n (%) . | 40 mg (N = 7) n (%) . |
|---|---|---|---|
| NHL other than ATL | Number of patients | 5 | 3 |
| CR | 0 (0) | 1 (33.3) | |
| CRu | 1 (20.0) | 1 (33.3) | |
| SD | 2 (40.0) | 1 (33.3) | |
| PD | 2 (40.0) | 0 (0) | |
| Objective response | CR, CRu or PR | 1 (20.0) | 2 (66.7) |
| Disease control | CR, CRu, PR or SD | 3 (60.0) | 3 (100) |
| ATL | Number of patients | 1 | 4 |
| PR | 0 (0) | 3 (75.0) | |
| SD | 1 (100) | 1 (25.0) | |
| Objective response | CR or PR | 0 (0.0) | 3 (75.0) |
| Disease control | CR, PR or SD | 1 (100) | 4 (100) |
| Lesion . | Response . | 30 mg (N = 6) n (%) . | 40 mg (N = 7) n (%) . |
|---|---|---|---|
| NHL other than ATL | Number of patients | 5 | 3 |
| CR | 0 (0) | 1 (33.3) | |
| CRu | 1 (20.0) | 1 (33.3) | |
| SD | 2 (40.0) | 1 (33.3) | |
| PD | 2 (40.0) | 0 (0) | |
| Objective response | CR, CRu or PR | 1 (20.0) | 2 (66.7) |
| Disease control | CR, CRu, PR or SD | 3 (60.0) | 3 (100) |
| ATL | Number of patients | 1 | 4 |
| PR | 0 (0) | 3 (75.0) | |
| SD | 1 (100) | 1 (25.0) | |
| Objective response | CR or PR | 0 (0.0) | 3 (75.0) |
| Disease control | CR, PR or SD | 1 (100) | 4 (100) |
Notes: Patients with no tumor assessment evaluation are considered non-responders. Abbreviations: CR, complete response; CRu, unconfirmed complete response; NHL, non-Hodgkin’s lymphoma; PD, progressive disease; PR, partial response; SD, stable disease.
| Lesion . | Response . | 30 mg (N = 6) n (%) . | 40 mg (N = 7) n (%) . |
|---|---|---|---|
| NHL other than ATL | Number of patients | 5 | 3 |
| CR | 0 (0) | 1 (33.3) | |
| CRu | 1 (20.0) | 1 (33.3) | |
| SD | 2 (40.0) | 1 (33.3) | |
| PD | 2 (40.0) | 0 (0) | |
| Objective response | CR, CRu or PR | 1 (20.0) | 2 (66.7) |
| Disease control | CR, CRu, PR or SD | 3 (60.0) | 3 (100) |
| ATL | Number of patients | 1 | 4 |
| PR | 0 (0) | 3 (75.0) | |
| SD | 1 (100) | 1 (25.0) | |
| Objective response | CR or PR | 0 (0.0) | 3 (75.0) |
| Disease control | CR, PR or SD | 1 (100) | 4 (100) |
| Lesion . | Response . | 30 mg (N = 6) n (%) . | 40 mg (N = 7) n (%) . |
|---|---|---|---|
| NHL other than ATL | Number of patients | 5 | 3 |
| CR | 0 (0) | 1 (33.3) | |
| CRu | 1 (20.0) | 1 (33.3) | |
| SD | 2 (40.0) | 1 (33.3) | |
| PD | 2 (40.0) | 0 (0) | |
| Objective response | CR, CRu or PR | 1 (20.0) | 2 (66.7) |
| Disease control | CR, CRu, PR or SD | 3 (60.0) | 3 (100) |
| ATL | Number of patients | 1 | 4 |
| PR | 0 (0) | 3 (75.0) | |
| SD | 1 (100) | 1 (25.0) | |
| Objective response | CR or PR | 0 (0.0) | 3 (75.0) |
| Disease control | CR, PR or SD | 1 (100) | 4 (100) |
Notes: Patients with no tumor assessment evaluation are considered non-responders. Abbreviations: CR, complete response; CRu, unconfirmed complete response; NHL, non-Hodgkin’s lymphoma; PD, progressive disease; PR, partial response; SD, stable disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
